Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (2)
P 2 (1)
P 3 (1)

Trial Status

Recruiting2
Enrolling By Invitation1
Not Yet Recruiting1
Active Not Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT04145115Phase 2Active Not RecruitingPrimary

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

NCT07468136Phase 1Not Yet Recruiting

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

NCT05303519Phase 3Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT06896110Phase 1Enrolling By Invitation

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

NCT06623565Not ApplicableRecruiting

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

Showing all 5 trials

Research Network

Activity Timeline